TY - JOUR
T1 - Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen
AU - Bertelli, Gianfilippo
AU - Valenzano, Mario
AU - Costantini, Sergio
AU - Rissone, Roberto
AU - Angiolini, Catia
AU - Signorini, Alessandra
AU - Gustavino, Claudio
PY - 2000
Y1 - 2000
N2 - Objectives. Sonohysterography (SHG) has been proposed as a useful tool for the surveillance of the endometrium in patients receiving tamoxifen. This study aimed to assess the value of SHG in asymptomatic patients who would have been biopsy candidates because of abnormal transvaginal ultrasound (TVUS) results. Methods. The study population included postmenopausal breast cancer patients receiving adjuvant tamoxifen who had asymptomatic abnormalities at TVUS (endometrial thickness ≥8 mm or endometrial echo not adequately visualized). SHG was performed with an Aloka SSD 680 system using a 5-MHz vaginal probe, with sterile saline solution as contrast medium. Results. Forty-one patients entered the study. A regular endometrial echo was identified by SHG in 9 patients (21.9%). Histology was obtained in the remaining 32 patients with positive (n = 27, 65.8%) or unsuccessful (n = 5, 12.2%) SHG. Benign polyps (n = 15, 36.6%) and endometrial atrophy (n = 14, 34.1%) were the most common findings; 3 patients (7.3%) had simple hyperplasia. Conclusions. Breast cancer patients with asymptomatic, tamoxifen-associated TVUS abnormalities have little additional benefit from SHG. More than 2/3 remain candidates for biopsy, which usually yields benign or insignificant findings. (C) 2000 Academic Press.
AB - Objectives. Sonohysterography (SHG) has been proposed as a useful tool for the surveillance of the endometrium in patients receiving tamoxifen. This study aimed to assess the value of SHG in asymptomatic patients who would have been biopsy candidates because of abnormal transvaginal ultrasound (TVUS) results. Methods. The study population included postmenopausal breast cancer patients receiving adjuvant tamoxifen who had asymptomatic abnormalities at TVUS (endometrial thickness ≥8 mm or endometrial echo not adequately visualized). SHG was performed with an Aloka SSD 680 system using a 5-MHz vaginal probe, with sterile saline solution as contrast medium. Results. Forty-one patients entered the study. A regular endometrial echo was identified by SHG in 9 patients (21.9%). Histology was obtained in the remaining 32 patients with positive (n = 27, 65.8%) or unsuccessful (n = 5, 12.2%) SHG. Benign polyps (n = 15, 36.6%) and endometrial atrophy (n = 14, 34.1%) were the most common findings; 3 patients (7.3%) had simple hyperplasia. Conclusions. Breast cancer patients with asymptomatic, tamoxifen-associated TVUS abnormalities have little additional benefit from SHG. More than 2/3 remain candidates for biopsy, which usually yields benign or insignificant findings. (C) 2000 Academic Press.
KW - Adjuvant hormone treatment of
KW - Adverse effects
KW - Breast cancer
KW - Endometrial cancer
KW - Sonohysterography
KW - Tamoxifen
KW - Transvaginal ultrasound
UR - http://www.scopus.com/inward/record.url?scp=0033823191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033823191&partnerID=8YFLogxK
U2 - 10.1006/gyno.2000.5876
DO - 10.1006/gyno.2000.5876
M3 - Article
C2 - 10985880
AN - SCOPUS:0033823191
VL - 78
SP - 275
EP - 277
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3 I
ER -